1-hydroxymethylmidazolam has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, BC; Hee, KH; Lee, LS; Sapari, NS; Seng, KY; Soon, GH; Soong, R | 1 |
| Chua, C; Fan, L; Goh, BC; Khoo, YM; Lee, HS; Lim, R; Ong, AB; Wang, L | 1 |
1 trial(s) available for 1-hydroxymethylmidazolam and Neoplasms
| Article | Year |
|---|---|
CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.
Topics: Adult; Aged; Anti-Anxiety Agents; Asian People; Bilirubin; Body Weight; Creatinine; Cytochrome P-450 CYP3A; Female; Genotype; Glucuronosyltransferase; Humans; Injections, Intravenous; Male; Midazolam; Middle Aged; Neoplasms; Polymorphism, Genetic | 2014 |
1 other study(ies) available for 1-hydroxymethylmidazolam and Neoplasms
| Article | Year |
|---|---|
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asia; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Half-Life; Humans; Infusions, Intravenous; Male; Midazolam; Middle Aged; Neoplasms; Oxidoreductases, N-Demethylating; Phenotype | 2003 |